What is Cumberland Pharmaceuticals Inc. (CPIX)?

Cumberland Pharmaceuticals Inc. (CPIX) is a stock in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry. View full analysis on Stocks360.

What is the current price of CPIX?

The current price of CPIX is $4.69. Prices are updated in real time on Stocks360.

What is CPIX's price-to-earnings (PE) ratio?

CPIX's trailing twelve-month PE ratio is -6.56, based on current price and earnings per share data available on Stocks360.

What is CPIX's market capitalization?

CPIX's market capitalization is $70,270,739.00, placing it in the small-cap tier.

Does CPIX pay a dividend?

Yes. CPIX has a trailing twelve-month dividend yield of 0.32%. Dividend data is sourced from financial market providers and displayed on Stocks360.

Cumberland Pharmaceuticals Inc. (CPIX)

Stock analysis · NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

$4.69

Market Cap

$70.27M

PE (TTM)

-6.56

EPS (TTM)

N/A

Dividend Yield

31.98%

Beta

0.10

Day Range

$4.37 – $4.76

52-wk Range

$1.85 – $9.28

Avg Volume

N/A

Volume

116.83K

Cumberland Pharmaceuticals Inc. (CPIX) is a publicly traded company in the Healthcare sector. Latest price: $4.69. Market cap $70.27M. Trailing PE -6.56. Dividend yield 31.98%. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-31 · $2.99 2026-10-30 · $4.69 (+56.86%)

Earnings

Most Recent

Aug 4, 2026

EPS $-0.20 vs est. $-0.13

Missed by $0.07

Next Earnings

Nov 3, 2026

EPS estimate $-0.13

Proprietary Signals

Signal snapshot temporarily unavailable.

About Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc. functions as a specialized pharmaceutical enterprise, primarily involved in the procurement, advancement, and commercialization of prescription medications. Its strategic focus areas include acute hospital care, gastroenterology, rheumatology, and oncology, with operations spanning both the United States and global markets. The company's existing product line includes: Acetadote: an injectable solution for treating acetaminophen poisoning. Caldolor: an injectable medication for managing pain and fever. Kristalose: a prescription oral laxative solution effective for chronic and acute constipation. Omeclamox-Pak: used in the treatment of Helicobacter pylori infection and duodenal ulcer disease. Vaprisol: an injectable therapy for euvolemic and hypervolemic hyponatremia. Vibativ: an injectable antibiotic prescribed for severe bacterial infections, including those acquired in hospitals or associated with ventilators, as well as complex skin and skin structure infections. In its development pipeline, Cumberland is advancing: RediTrex injection: designed to treat active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, along with disabling…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-6.56×
P/S (TTM)	2.25×
P/B	4.03×
PEG	0.05×
P/FCF (TTM)	-63.25×
EV / EBITDA	-14.01×
EV / Sales	2.27×
Earnings Yield	-15.10%
Free Cash Flow Yield	-1.58%
Dividend Yield	31.98%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$71.12M
Revenue (TTM)	$31.27M
Net Income (TTM)	-$10.61M
Free Cash Flow (TTM)	-$779.10K
Net Debt	$851.78K
Working Capital	-$1.55M
Gross Margin	83.37%
Operating Margin	-30.79%
Net Margin	-33.92%
Return on Equity	-47.10%
Return on Invested Capital	-34.15%